TY - JOUR
TI - Sodium–glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
AU - Seferović, P.M.
AU - Fragasso, G.
AU - Petrie, M.
AU - Mullens, W.
AU - Ferrari, R.
AU - Thum, T.
AU - Bauersachs, J.
AU - Anker, S.D.
AU - Ray, R.
AU - Çavuşoğlu, Y.
AU - Polovina, M.
AU - Metra, M.
AU - Ambrosio, G.
AU - Prasad, K.
AU - Seferović, J.
AU - Jhund, P.S.
AU - Dattilo, G.
AU - Čelutkiene, J.
AU - Piepoli, M.
AU - Moura, B.
AU - Chioncel, O.
AU - Ben Gal, T.
AU - Heymans, S.
AU - de Boer, R.A.
AU - Jaarsma, T.
AU - Hill, L.
AU - Lopatin, Y.
AU - Lyon, A.R.
AU - Ponikowski, P.
AU - Lainščak, M.
AU - Jankowska, E.
AU - Mueller, C.
AU - Cosentino, F.
AU - Lund, L.
AU - Filippatos, G.S.
AU - Ruschitzka, F.
AU - Coats, A.J.S.
AU - Rosano, G.M.C.
JO - European Journal of Heart Failure
PY - 2020
VL - 22
TODO - 9
SP - 1495-1503
PB - John Wiley and Sons Ltd
SN - null
TODO - 10.1002/ejhf.1954
TODO - amino terminal pro brain natriuretic peptide;  angiotensin receptor antagonist;  beta adrenergic receptor blocking agent;  canagliflozin;  dapagliflozin;  dipeptidyl carboxypeptidase inhibitor;  empagliflozin;  ivabradine;  ketone body;  mineralocorticoid antagonist;  placebo;  sacubitril plus valsartan;  sodium glucose cotransporter 2 inhibitor;  sotagliflozin;  cotransporter;  glucose;  sodium, albuminuria;  Article;  cardiac resynchronization therapy;  cardiovascular mortality;  chronic kidney failure;  drug efficacy;  drug mechanism;  drug safety;  electrolyte disturbance;  exercise tolerance;  functional status;  glucosuria;  heart failure;  heart failure with preserved ejection fraction;  heart failure with reduced ejection fraction;  heart left ventricle ejection fraction;  heart left ventricle mass;  heart ventricle remodeling;  hospitalization;  human;  hyperuricosuria;  hypoglycemia;  insulin resistance;  natriuresis;  New York Heart Association class;  non insulin dependent diabetes mellitus;  nonhuman;  priority journal;  quality of life;  renal protection;  cardiology;  complication;  glycemic control;  heart failure;  heart left ventricle function;  heart stroke volume;  non insulin dependent diabetes mellitus, Cardiology;  Diabetes Mellitus, Type 2;  Glucose;  Glycemic Control;  Heart Failure;  Humans;  Sodium;  Sodium-Glucose Transporter 2 Inhibitors;  Stroke Volume;  Symporters;  Ventricular Function, Left
TODO - Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus have demonstrated beneficial effects for three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from cardiovascular causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without type 2 diabetes mellitus. A number of additional trials in HF patients with reduced and/or preserved left ventricular ejection fraction are ongoing and/or about to be reported. The present position paper summarises recent clinical trial evidence and discusses the role of SGLT2 inhibitors in the treatment of HF, pending the results of ongoing trials in different populations of patients with HF. © 2020 European Society of Cardiology
ER -